search
Back to results

Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients

Primary Purpose

Diminished Ovarian Reserve, Infertility, Female

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Medical prescription before ovulation
Medical prescription after ovulation
Sponsored by
Peking University Third Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diminished Ovarian Reserve focused on measuring traditional Chinese medicine, in vitro fertilization and embryo transfer, diminished ovarian reserve

Eligibility Criteria

20 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female, 20 years old ≤ age ≤ 42 years old;
  2. The menstrual cycle is generally regular; 21 days < menstrual cycle < 35 days;
  3. Those who meet the diagnostic criteria for DOR in Western medicine;
  4. Those who meet the TCM differential criteria of kidney deficiency syndrome;
  5. Those who are scheduled to undergo IVF-ET;
  6. Those who voluntarily participate in this clinical trial and sign a written informed consent.

Exclusion Criteria:

  1. Those who have a history of two or more spontaneous abortions (excluding biochemical pregnancy abortion) or three or more previous transplantations without achieving clinical pregnancy;
  2. Those who have premature ovarian failure or ovarian gonadotropin resistance syndrome;
  3. Those who have untreated uterine malformation or abnormality: double uterus, septate uterus (complete or incomplete);
  4. Those who have untreated unilateral or bilateral hydrosalpinx;
  5. Those who have uncured endometrial diseases (such as endometritis, endometrial polyps, endometriosis), adenomyosis, intrauterine adhesions, etc., and those with uterine fibroids of more than 4 cm;
  6. Those who have endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, hypothyroidism, abnormal adrenal function, etc., which affect ovulation;
  7. Infertile patients with abnormal ovarian function caused by immunological factors, genetic factors or congenital physiological defects;
  8. Those who have received pelvic radiotherapy;
  9. Those who are known or suspected of having sex hormone-related malignant tumors;
  10. Those who are allergic or intolerable to the medications involved in the study;
  11. Those with contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormal liver and renal function, diabetes, hypertension, thyroid disease, symptomatic heart disease, moderate to severe anemia, history of malignant tumor or history of thromboembolism or thrombosis formation tendency, serious mental illness, acute infection of urogenital system, sexually transmitted disease, extremely bad habits such as drug use, exposure to teratogenic radiation, poison, drugs (such as prednisone and other hormones, epinephrine, antibiotics, antihypertensive drugs, cardiovascular and cerebrovascular drugs, antiviral drugs) and are still under the effect of the drugs; and those whose uterus is unable to perform the function of pregnancy or who are intolerant of pregnancy due to physical diseases during pregnancy;
  12. Those who have taken other TCMs or proprietary Chinese medicines that can invigorate the kidney or affect the evaluation of drug efficacy in the past 30 days;
  13. Other patients who are deemed unsuitable to participate in this study by the researchers;
  14. Those who are participating in other clinical trials;
  15. Those who do not agree to participate in this study or do not sign the informed consent form.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    administration for 2 menstrual cycles group

    administration for 3 menstrual cycles group

    Arm Description

    This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.

    This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.

    Outcomes

    Primary Outcome Measures

    Number of oocytes retrieved
    The number of oocytes retrieved by puncture under the guidance of vaginal ultrasound

    Secondary Outcome Measures

    High-quality embryo rate (%)
    Number of high-quality embryos / the total number of normal cleavage embryos × 100%
    Clinical pregnancy rate
    Ultrasound monitoring is performed 30 days after embryo transfer
    Compliance with the treatment plan
    The situation of continuous treatment of the research subjects is recorded; the compliance of the experimental group = the number of cases who receive continuous treatment for 2 months / the total number of patients in the experimental group; the compliance of the control group = the number of cases who receive continuous treatment for 3 months / the total number of patients in the control group
    Gonadotrophin (Gn) administration day
    Record the total gonadotrophin (Gn) administration day
    Gn dosage
    Record the average dose of Gn administration
    Levels of LH
    Obtained by blood sampling
    Levels of E2
    Obtained by blood sampling
    Levels of P
    Obtained by blood sampling
    Antral follicle count (AFC)
    Changes of AFC before and after TCM intervention
    Levels of FSH
    Obtained by blood sampling
    Levels of AMH
    Obtained by blood sampling
    Health economics indicators
    Average daily cost and total cost

    Full Information

    First Posted
    October 9, 2022
    Last Updated
    October 26, 2022
    Sponsor
    Peking University Third Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05577455
    Brief Title
    Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients
    Official Title
    Non-inferiority Randomized Controlled Study on Kidney Tonifying and Blood Circulation Regulating Therapy (Bu Shen Tiao Xue) of Different Intervention Courses in Improving IVF-ET Pregnancy Outcomes in DOR Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    November 10, 2022 (Anticipated)
    Primary Completion Date
    December 30, 2024 (Anticipated)
    Study Completion Date
    December 30, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Peking University Third Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Patients with diminished ovarian reserve (DOR) who undergo in vitro fertilization and embryo transfer (IVF-ET) are included as the research subjects. The effects of Traditional Chinese Medicine (TCM) for kidney tonifying and blood circulation regulating of different intervention courses on ovarian hyporesponsiveness, IVF-ET outcome and clinical compliance in DOR patients are studied by a non-inferiority randomized controlled trial. The purpose is to identify the breakthrough point and treatment timing of TCM treatment, explore the best treatment course of TCM, and optimize the TCM therapeutic regimen.
    Detailed Description
    IVF-ET is one of the major techniques to treat infertility in DOR patients, but poor ovarian response and low pregnancy rate have been the bottleneck problems. China has original advantages in Traditional Chinese Medicine (TCM) treatment. The kidney tonifying and blood circulation regulating therapy is a pre-IVF-ET intervention treatment characterized by sequential treatment according to menstrual cycle formed in the previous investigations by the research group. It can ameliorate ovarian hyporesponsiveness and improve the success rate of IVF-ET, but the compliance is poor due to the long intervention course. Identifying the time point of TCM intervention to further optimize the treatment plan is the key to improving the pregnancy rate. Therefore, DOR patients who receive IVF-ET are enrolled as the research objects in this project, who are divided into the experimental group and control group with a randomized controlled non-inferiority design, and receive sequential TCM therapy for kidney tonifying and blood circulation regulating from the fifth day of menstruation at the second menstrual cycle and the third menstrual cycle prior to IVF-ET, respectively, until the day of human chorionic gonadotrophin (hCG) administration. The number of oocytes retrieved, the rate of high-quality embryos, the dosage and administration days of Gn, the levels of estradiol (E2) and progesterone (P) and the clinical pregnancy rate on hCG day are compared between the two groups. Meanwhile, the compliance of patients in the two groups with different treatment regimens is compared. This project aims to verify that the efficacy of the treatment plan implemented from the second menstrual cycle prior to IVF-ET may not be inferior to that from the third menstrual cycle prior to IVF-ET on improving the pregnancy outcomes of DOR patients, while the compliance is better. The results of the study will provide a reference basis for the precise treatment of TCM prior to IVF-ET.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diminished Ovarian Reserve, Infertility, Female
    Keywords
    traditional Chinese medicine, in vitro fertilization and embryo transfer, diminished ovarian reserve

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    After the patients complete the relevant examinations, and those who meet the inclusion criteria sign the informed consent, they are sequentially assigned to two groups according to the randomization table. The intervention begins from the second menstrual cycle prior to IVF-ET in the experimental group and third menstrual cycle prior to IVF-ET in the control group. TCM treatment is initiated on the 5th day of menstruation in both groups, and medical prescriptions before and after ovulation are administered successively. Subjects do not take any medicine on the 1st to 4th day of menstruation and medications are discontinued on the day of HCG. The TCM is decocted by our hospital, and patients are instructed to take one dose of the the decoction warm per day (400 ml per dose) one hour after meals twice (once in the morning and once in the evening). The occurrence of spontaneous pregnancy and adverse reactions are recorded and dealt with promptly throughout the drug application period.
    Masking
    ParticipantCare Provider
    Allocation
    Randomized
    Enrollment
    266 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    administration for 2 menstrual cycles group
    Arm Type
    Experimental
    Arm Description
    This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.
    Arm Title
    administration for 3 menstrual cycles group
    Arm Type
    Active Comparator
    Arm Description
    This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.
    Intervention Type
    Drug
    Intervention Name(s)
    Medical prescription before ovulation
    Intervention Description
    Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
    Intervention Type
    Drug
    Intervention Name(s)
    Medical prescription after ovulation
    Intervention Description
    Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
    Primary Outcome Measure Information:
    Title
    Number of oocytes retrieved
    Description
    The number of oocytes retrieved by puncture under the guidance of vaginal ultrasound
    Time Frame
    up to 15 weeks from enrollment
    Secondary Outcome Measure Information:
    Title
    High-quality embryo rate (%)
    Description
    Number of high-quality embryos / the total number of normal cleavage embryos × 100%
    Time Frame
    up to 15 weeks from enrollment
    Title
    Clinical pregnancy rate
    Description
    Ultrasound monitoring is performed 30 days after embryo transfer
    Time Frame
    up to 15 weeks from enrollment
    Title
    Compliance with the treatment plan
    Description
    The situation of continuous treatment of the research subjects is recorded; the compliance of the experimental group = the number of cases who receive continuous treatment for 2 months / the total number of patients in the experimental group; the compliance of the control group = the number of cases who receive continuous treatment for 3 months / the total number of patients in the control group
    Time Frame
    up to 15 weeks from enrollment
    Title
    Gonadotrophin (Gn) administration day
    Description
    Record the total gonadotrophin (Gn) administration day
    Time Frame
    up to 15 weeks from enrollment
    Title
    Gn dosage
    Description
    Record the average dose of Gn administration
    Time Frame
    up to 15 weeks from enrollment
    Title
    Levels of LH
    Description
    Obtained by blood sampling
    Time Frame
    up to 15 weeks from enrollment
    Title
    Levels of E2
    Description
    Obtained by blood sampling
    Time Frame
    up to 15 weeks from enrollment
    Title
    Levels of P
    Description
    Obtained by blood sampling
    Time Frame
    up to 15 weeks from enrollment
    Title
    Antral follicle count (AFC)
    Description
    Changes of AFC before and after TCM intervention
    Time Frame
    up to 15 weeks from enrollment
    Title
    Levels of FSH
    Description
    Obtained by blood sampling
    Time Frame
    up to 15 weeks from enrollment
    Title
    Levels of AMH
    Description
    Obtained by blood sampling
    Time Frame
    up to 15 weeks from enrollment
    Title
    Health economics indicators
    Description
    Average daily cost and total cost
    Time Frame
    up to 15 weeks from enrollment

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    42 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Female, 20 years old ≤ age ≤ 42 years old; The menstrual cycle is generally regular; 21 days < menstrual cycle < 35 days; Those who meet the diagnostic criteria for DOR in Western medicine; Those who meet the TCM differential criteria of kidney deficiency syndrome; Those who are scheduled to undergo IVF-ET; Those who voluntarily participate in this clinical trial and sign a written informed consent. Exclusion Criteria: Those who have a history of two or more spontaneous abortions (excluding biochemical pregnancy abortion) or three or more previous transplantations without achieving clinical pregnancy; Those who have premature ovarian failure or ovarian gonadotropin resistance syndrome; Those who have untreated uterine malformation or abnormality: double uterus, septate uterus (complete or incomplete); Those who have untreated unilateral or bilateral hydrosalpinx; Those who have uncured endometrial diseases (such as endometritis, endometrial polyps, endometriosis), adenomyosis, intrauterine adhesions, etc., and those with uterine fibroids of more than 4 cm; Those who have endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, hypothyroidism, abnormal adrenal function, etc., which affect ovulation; Infertile patients with abnormal ovarian function caused by immunological factors, genetic factors or congenital physiological defects; Those who have received pelvic radiotherapy; Those who are known or suspected of having sex hormone-related malignant tumors; Those who are allergic or intolerable to the medications involved in the study; Those with contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormal liver and renal function, diabetes, hypertension, thyroid disease, symptomatic heart disease, moderate to severe anemia, history of malignant tumor or history of thromboembolism or thrombosis formation tendency, serious mental illness, acute infection of urogenital system, sexually transmitted disease, extremely bad habits such as drug use, exposure to teratogenic radiation, poison, drugs (such as prednisone and other hormones, epinephrine, antibiotics, antihypertensive drugs, cardiovascular and cerebrovascular drugs, antiviral drugs) and are still under the effect of the drugs; and those whose uterus is unable to perform the function of pregnancy or who are intolerant of pregnancy due to physical diseases during pregnancy; Those who have taken other TCMs or proprietary Chinese medicines that can invigorate the kidney or affect the evaluation of drug efficacy in the past 30 days; Other patients who are deemed unsuitable to participate in this study by the researchers; Those who are participating in other clinical trials; Those who do not agree to participate in this study or do not sign the informed consent form.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Xiyan Xin
    Phone
    +86 0108226
    Ext
    4621
    Email
    xinxiyan198234@163.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Dong Li
    Organizational Affiliation
    Peking University Third Hospital
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients

    We'll reach out to this number within 24 hrs